Welcome to our dedicated page for Amphastar Pharma SEC filings (Ticker: AMPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amphastar Pharmaceuticals filings document the regulatory disclosures of a Delaware biopharmaceutical company focused on generic and proprietary injectable, inhalation, and intranasal products, along with active pharmaceutical ingredient products. Form 8-K reports furnish operating results, product revenue commentary, non-GAAP measures, and material business updates tied to the company's pharmaceutical products business.
Amphastar's SEC filings also cover governance and capital-structure matters, including proxy disclosures, executive compensation, employment agreements, equity-compensation dilution, and share repurchase authorizations. Material agreement filings describe licensing rights for a corticotropin compound, supply arrangements involving a Chinese subsidiary, related-party review procedures, and commercial terms that affect the company's pipeline, manufacturing, and distribution activities.
Amphastar Pharmaceuticals entered a license agreement with Nanjing Anji Biotechnology granting Amphastar exclusive rights in the United States and Canada to develop, make, use and commercialize products incorporating certain compounds, including three identified Licensed Products. Amphastar paid an $0.75 million earnest payment and a $5.25 million upfront fee on signing and agreed to up to $42 million in development milestones and up to $225 million in sales milestones, plus royalty payments capped at $22.5 million per product per year and a $60 million accumulated cap per product. Amphastar will share a percentage of sublicense income with Anji, and Anji will pay Amphastar royalties on net sales tied to Amphastar-licensed patents outside the Territory.
The agreement term runs product-by-product and region-by-region to the tenth anniversary of first commercial sale with an Amphastar option to extend up to ten additional years or until patent claims lapse. The company disclosed customary forward-looking statements and identified risks including regulatory approval, commercialization success, legal and regulatory changes, and supply-chain disruptions, and incorporated the full Agreement by reference to be filed as an exhibit.
Amphastar Pharmaceuticals (AMPH) – SEC Form 4
Director Floyd F. Petersen disclosed the sale of 500 common shares on 01 Aug 2025 at a weighted-average price of $20.8315. The transaction was executed under a Rule 10b5-1 trading plan adopted 26 Nov 2024, indicating it was pre-scheduled rather than discretionary. After the sale, Petersen directly owns 77,031 shares, so the disposition equals roughly 0.6 % of his stake and is immaterial relative to Amphastar’s total share count. No derivative securities activity or additional insider trades were reported.
The filing therefore conveys routine insider diversification without signaling a change in corporate fundamentals or outlook.
Form 4 Overview – Amphastar Pharmaceuticals, Inc. (AMPH)
Director Floyd F. Petersen disclosed the sale of 500 shares of Amphastar Pharmaceuticals common stock on 07 July 2025 (trade date 07/02/2025) at a weighted-average price of $23.4679 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 26 November 2024. Following the sale, Petersen’s direct ownership stands at 77,531 shares.
No derivative securities were involved and no other transactions were reported.
- Percentage of holdings sold: roughly 0.6 % of the director’s reported stake.
- The filing indicates continued direct ownership; no change to indirect holdings was reported.
- Rule 10b5-1 plan suggests the trade was scheduled in advance, reducing concerns over information asymmetry.
Given the modest size of the sale relative to total ownership and the use of a 10b5-1 plan, the market impact is likely limited.